Analysis of efficacy
MAY, LIVER METASTASES, METASTASES
Follow-up was censored on May 31, 2021, with a median of 24.3 (6.1–59.8 months). The 2-year PFS and OS were higher in the S1-MT group (PFS 25.0% and OS 43.2%) than in the non-MT group (PFS 14.7% and OS 20.0%). Compared with the non-MT group, S1-MT significantly prolonged median PFS (16.9 vs. 9.3 months, Comparison of PFS (Across the patient subgroups, we observed a consistent benefit in favour of S1-MT in terms of PFS and OS, including for different ages, sexes, liver metastases, ECOG scores, first-line treatment regimens, and multisite metastases (all Subgroup analysis of PFS (